How the EU’s pharmaceutical reform changes regulatory protection, medicine supply, generic entry, antimicrobial incentives and orphan exclusivity
Why should I read this?
The European Union is close to completing the most significant overhaul of its pharmaceutical legislation in more than two decades. In September 2026, the Council adopted its first-reading position on the EU Pharma Package, which is made up of a new Directive establishing a Union code for medicinal products for human use and a new Regulation on Union authorisation procedures and the European Medicines Agency. The new framework has two main goals: to make the sector more competitive and to make it more accountable.
- The key changes are as follows:
- Data protection stays at eight years, market protection is one year.
- Member States can require companies to supply protected medicines in sufficient quantities.
- A broader Bolar exemption is to be introduced which supports day one generic launch.
- A transferable exclusivity voucher rewards new priority antibiotics.
- Orphan medicines receive nine years of market exclusivity, or eleven for "breakthrough" orphans.
What should I do?
- The Regulation and the Directive will only enter into force once they are published in the Official Journal of the European Union. Even so, companies should start preparing now and adapt their operations to the new requirements. Priority areas include:
- revisit lifecycle and filing strategies to secure the available protection extensions.
- set up shortage prevention plans and notification procedures that can meet the new notice periods.
- check whether pre-expiry studies, trials and preparations fall within the new Bolar exemption. Plan for day one launch.
- consider whether your organisation is creating priority antibiotics, and whether the voucher may be available.
Time is running short for companies, regulators, hospitals and Member States to get ready.
What else do I need to know about the EU Pharma Package?
The package aims to balance several objectives: maintaining the competitiveness of the European pharmaceutical industry, rewarding innovation, preventing medicine shortages, and improving patient access to treatments across the EU.
- Regulatory reform: The eight-year regulatory data protection period remains unchanged, while the subsequent market protection period is reduced from two years to one. However, companies may obtain additional protection in specific circumstances, allowing total regulatory protection to reach up to 11 years. It should also be noted that reference medicinal products for which a marketing authorisation application is submitted before the new rules take effect will continue to benefit from the data protection regime under Directive 2001/83/EC.
- Availability of medicines: The new framework introduces stricter obligations to address medicine shortages. Marketing authorisation holders will be required to notify the competent authorities in advance of any permanent withdrawal of a medicinal product from the market, any requests to withdraw a marketing authorisation, temporary suspension of marketing, or supply disruptions expected to last more than two weeks. They must also implement measures to prevent and manage shortages.
- Bolar exemption: The package builds on the existing Bolar exemption. Studies, trials and steps taken to obtain authorisation for generic versions will not infringe IP rights, so they can be ready on day one. The exemption also covers conducting health technology assessments, obtaining pricing and reimbursement approval, complying with subsequent practical requirements and submitting an application on procurement tenders.
- Antibiotic voucher: To encourage development of priority antibiotics, the package includes a transferable exclusivity voucher which grants one year of additional market protection for a product of the voucher holder’s choice. The voucher cannot be used on products which have annual gross sales of more than €490 million in the preceding four years.
- Orphan medicines: Orphan medicines for rare conditions will be granted an extended exclusivity of nine years. Breakthrough orphan medicines will receive an additional two years of market exclusivity, totalling eleven years. A medicine qualifies as a breakthrough medicine where no product is authorised in the EU for that condition and it leads to a clinically relevant reduction in sickness or mortality.
Given how long ago the last major revision of EU pharmaceutical legislation took place, this package is a substantial step forward, particularly considering that the market has changed profoundly since then.
Once formally adopted and published in the Official Journal, Member States will be required to transpose the Directive into national law, while the Regulation will apply directly. Both are expected to apply 24 months after entry into force.
For more information on the EU Pharma Package
Tobias Maier
Anne Servoir
Christina Miller
Further reading on the EU Pharma Package
EU: Pharmaceutical Law Reform
Global Life Sciences & Healthcare Bulletin
The future of the UK life sciences sector: Balancing innovation and regulation
Eversheds Sutherland takes all reasonable care to ensure that the materials, information and documents, including but not limited to articles, newsletters, reports and blogs (""Materials"") on the Eversheds Sutherland website are accurate and complete. However, the Materials are provided for general information purposes only, not for the purpose of providing legal advice, and do not necessarily reflect the present law or regulations. The Materials should not be construed as legal advice on any matter.
The Materials may not reflect the most current legal developments. The content and interpretation of the Materials and the law addressed in the Materials are subject to revision.
No representation or warranty, express or implied, is made as to the accuracy or completeness of the Materials and therefore the Materials should not be relied upon. Eversheds Sutherland disclaims all liability in respect of actions taken or not taken based on any or all of the contents of the Materials to the fullest extent permitted by law. The Materials are not intended to be comprehensive or to include advice on which you may rely. You should always consult a suitably qualified Lawyer/Attorney on any specific legal matter.
Any views expressed through the Materials are the views of the individual author and may not reflect the views of Eversheds Sutherland or any other individual Lawyer/Attorney.